Inactive Instrument

Syneos Health, Inc.

Equities

SYNH

US87166B1026

Biotechnology & Medical Research

This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Syneos Health Names Colin Shannon CEO MT
Syneos Health, Inc. Announces Chief Executive Officer Changes CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P 400 CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P 400 Health Care CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P Composite 1500 CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P TMI Index CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P 1000 CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from S&P Global BMI Index CI
Syneos Health, Inc. Announces Management Changes CI
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from NASDAQ Composite Index CI
Syneos Health, Inc.'s Equity Buyback announced on June 1, 2022, has expired. CI
Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C completed the acquisition of Syneos Health, Inc. from a group of shareholders. CI
Civitas Resources to be Added to S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600 MT
Syneos Health, Inc.(NasdaqGS:SYNH) dropped from NASDAQ Biotechnology Index CI
Syneos Health Names Terttu Haring President, Clinical Sites & Patients CI
Syneos Health, Oracle Collaborate to Speed Up Patient Recruitment for Clinical Studies MT
Large LBO bond sales could prompt September US junk debt rush RE
Syneos Health, Star Parent Plan $1.70 Billion Senior Secured Notes Offering MT
European Commission Clears Joint Acquisition of Syneos Health MT
Tranche Update on Syneos Health, Inc.'s Equity Buyback Plan announced on June 1, 2022. CI
Syneos Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Syneos Health Gets Shareholder Approval for Acquisition Deal MT
Click Therapeutics Launches Additional Randomized Clinical Study in Migraine, Conducted in Partnership with Syneos Health CI
Syneos Health Appoints Hillary Bochniak as Chief Human Resources Officer CI
Syneos Health, uMotif to Collaborate on Digital Platform for Clinical Trials MT
Chart Syneos Health, Inc.
More charts
Syneos Health, Inc. is a biopharmaceutical solutions company that utilizes outsourced clinical drug development and commercialization services. The Company operates through two business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. The Clinical Solutions segment offers individual services including product development, project management, protocol development, investigational site recruitment, and clinical monitoring. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions (public relations, advertising, and medical communications), and consulting services. The Company's customers include small, mid-sized, and large companies in the biopharmaceutical, biotechnology, and medical device industries.
More about the company
  1. Stock
  2. Equities
  3. Stock Syneos Health, Inc. - Nyse
  4. News Syneos Health, Inc.
  5. European Commission Clears Joint Acquisition of Syneos Health
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW